227 related articles for article (PubMed ID: 6110956)
1. Delayed alloimmunisation by random single donor platelet transfusions. A randomised study to compare single donor and multiple donor platelet transfusions in cancer patients with severe thrombocytopenia.
Sintnicolaas K; Vriesendorp HM; Sizoo W; Stenfert Kroese WF; Haije WG; Hop WC; Abels J; Löwenberg B
Lancet; 1981 Apr; 1(8223):750-4. PubMed ID: 6110956
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
Messerschmidt GL; Makuch R; Appelbaum F; Ungerleider RS; Abrams R; O'Donnell J; Holohan TV; Fontana J; Wright D; Anagnou NP
Cancer; 1988 Aug; 62(4):795-801. PubMed ID: 3293762
[TBL] [Abstract][Full Text] [Related]
3. Platelet transfusions: the problem of refractoriness.
Murphy MF; Waters AH
Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
[TBL] [Abstract][Full Text] [Related]
4. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
Levy L; Woodfield DG
N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates.
McFarland JG; Anderson AJ; Slichter SJ
Br J Haematol; 1989 Nov; 73(3):380-6. PubMed ID: 2605125
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
7. [An evaluation of platelet transfusion response using HLA crossmatch-compatible donors in patients with platelet refractoriness].
Hyun J; Lim YM; Park KD; Han BY; Kim YH; Han KS; Park MH
Korean J Lab Med; 2009 Oct; 29(5):481-9. PubMed ID: 19893359
[TBL] [Abstract][Full Text] [Related]
8. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia.
Gmür J; von Felten A; Osterwalder B; Honegger H; Hörmann A; Sauter C; Deubelbeiss K; Berchtold W; Metaxas M; Scali G; Frick PG
Blood; 1983 Aug; 62(2):473-9. PubMed ID: 6871470
[TBL] [Abstract][Full Text] [Related]
9. Guidelines for platelet transfusions. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
Murphy MF; Brozovic B; Murphy W; Ouwehand W; Waters AH
Transfus Med; 1992 Dec; 2(4):311-8. PubMed ID: 1339584
[TBL] [Abstract][Full Text] [Related]
10. Canine platelet alloimmunization: the role of donor selection.
Slichter SJ; O'Donnell MR; Weiden PL; Storb R; Schroeder ML
Br J Haematol; 1986 Aug; 63(4):713-27. PubMed ID: 3730294
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
12. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
13. The current status of platelet and granulocyte transfusions.
Seidl S; Kilp M
Haematologia (Budap); 1980; 13(1-4):145-54. PubMed ID: 7019021
[TBL] [Abstract][Full Text] [Related]
14. Donor availability for platelet transfusion support of alloimmunized thrombocytopenic patients.
Duquesnoy RJ; Vieira J; Aster RH
Transplant Proc; 1977 Mar; 9(1):519-21. PubMed ID: 867500
[No Abstract] [Full Text] [Related]
15. Clinical aspects of platelet transfusion therapy.
Murphy MF
Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():34-8. PubMed ID: 7841778
[TBL] [Abstract][Full Text] [Related]
16. New strategies for the optimal use of platelet transfusions.
Blajchman MA; Slichter SJ; Heddle NM; Murphy MF
Hematology Am Soc Hematol Educ Program; 2008; ():198-204. PubMed ID: 19074082
[TBL] [Abstract][Full Text] [Related]
17. Prevention and management of platelet transfusion refractoriness.
Novotny VM
Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer.
Goldberg GL; Gibbon DG; Smith HO; DeVictoria C; Runowicz CD; Burns ER
J Clin Oncol; 1994 Nov; 12(11):2317-20. PubMed ID: 7964946
[TBL] [Abstract][Full Text] [Related]
19. [Substitution ofpolysensitized patients with platelets from HL-A typed single donors].
Gmür J; Baumberger U; von Felten A
Schweiz Med Wochenschr; 1976 Oct; 106(40):1358-9. PubMed ID: 1006253
[TBL] [Abstract][Full Text] [Related]
20. The relationship between donor-recipient lymphocytotoxicity and the transfusion response using HLA-matched platelet concentrates.
Herzig RH; Terasaki PI; Trapani RJ; Herzig GP; Graw RG
Transfusion; 1977; 17(6):657-61. PubMed ID: 595123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
